Joint Project Manager Transformational Medical Technologies (JPM-TMT)

03/11/2013

JPM-TMT issued an RFI on March 4, 2013 requesting information on the development of therapeutics for antibiotic resistant Biological Warfare Agents. The continuing emergence of multi-drug resistant bacteria is a problem recognized by DoD as well as other government agencies. DoD’s program within JPM-TMT is focused on bacteria classified as Biological Warfare Agents (BWAs). These bacteria—outlined in the RFI—have the potential to be genetically engineered or used as weapons. The goal is to develop long-term, broad-spectrum therapeutics to defeat antibiotic resistance should these bacteria become weaponized or naturally spread.

For detailed information and to respond to the RFI, please visit http://bit.ly/16bmMIf

11/20/2012

For those who participated in our Virtual Industry Day last Thursday – the slides from the presentations were posted to the website today. Visit: http://bit.ly/S6DwKN The audio files and Q&As are forthcoming. An e-mail will be sent to you with the details.

11/19/2012

For those who participated in our Virtual Industry Day last Thursday, we encourage you to help us improve these events by taking our short post-virtual industry day survey. A link was e-mailed to all participants. More info @ www3.natick.army.mil/JPEO-CBD/

this morning.

The purpose of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) Medical Virtual Industry Day (VID) is to:

10/31/2012

The Joint Program Executive Office for Chemical Biological Defense (JPEO-CBD) is hosting a Virtual Industry Day on 15 NOV 12 to create an open forum between key industry players and its combined Medical Project Management Offices. To register go to: www3.natick.army.mil/JPEO-CBD/

10/31/2012

LTC David Gibson shows his appreciation as BG Jess Scarbrough signs the Milestone B Acquisition Decision Memorandum (ADM) for JPM-TMT’s Emerging Infectious Diseases-Influenza medical countermeasure (EID-Flu MCM) acquisition program. An ADM is the official approval for the program to move to the Engineering and Manufacturing Development (EMD) phase. In the EMD phase, the EID-Flu MCM acquisition program will complete Phase 3 clinical trials required for U.S. Food and Drug Administration (FDA) approval and will submit a New Drug Application to the FDA. The program has contracted with Boston’s MediVector, Inc. to further develop Favipiravir (T-705), a broad-spectrum drug candidate that has shown to be efficacious against multiple strains of the flu, including the 2009 H1N1 virus and drug-resistant influenza strains. For more info, visit www.jpmtmt.mil

09/19/2012

The 2012 Joint Program Executive Office for Chemical and Biological Defense Advanced Planning Briefings for Industry (JPEO CBD APBI) starts today (through Friday) in Baltimore. Learn about future business opportunities in the industry and the direction of the Chemical Biological Defense Program (CBDP), and future DOD requirements.

09/17/2012

The Animal Model Development Workshop, co-sponsored by , , and , is Today! Attend this great opportunity to explore the scientific and regulatory challenges of developing medical countermeasures under the “Animal Rule.” At the workshop, you will get the chance to share current challenges and identify potential solutions or mitigation strategies for MCM development and animal models.

08/06/2012

A new study testing a drug candidate to treat Marburg virus demonstrated significant survival rates up to four days after exposure to the disease. Referred to as AVI-7288, the drug is a post-exposure prophylactic targeting the Marburg virus which may cause hemorrhagic fever, a severe, life-threatening disease that exhibits fever and bleeding. The development of AVI-7288 is funded by Joint Project Manager Transformational Medical Technologies (JPM-TMT). Sarepta Therapeutics—formerly AVIBioPharma—conducted the study to determine the efficacy of AVI-7288 when administered at various post-exposure time points. The results demonstrated a high degree of survival, between 83% and 100%, in each of four post-exposure cohorts that received daily treatments with AVI-7288 beginning immediately and then one, two and four days after infection. The placebo-treated control group had a 0% survival rate. See our full press release. http://bit.ly/MYHdlm

07/23/2012

Registration for the Animal Model Development Workshop is now open. To register, please visit http://bit.ly/Nr3Ahh. The workshop, co-sponsored by , , and , will explore the scientific and regulatory challenges of developing medical countermeasures under the “Animal Rule.” At the workshop, attendees will get the chance to share current challenges and identify potential solutions or mitigation strategies for MCM development and animal models.

The National Institute of Allergy and Infectious Diseases (NIAID), the Food and Drug Administration (FDA), the Transformational Medical Technologies (TMT), and Biomedical Advanced Research and Development Authority (BARDA) are holding an Animal Model Development Workshop to explore the scientific an...

06/28/2012

At the 2012 JIIM-IA Conference and Exhibition at Fort Leonard Wood, MO? Don't forget to attend today's JPEO-CBD Joint Project Managers' Program Updates panel presentation. LTC Gibson of 's EID-Flu Medical Countermeasure acquisition program will present updates about between 0820 to 1030 in the Abrams Theater.

06/26/2012

The 2012 Joint, Interagency, Intergovernmental, Multinational, Industry, and Academia (JIIM-IA), is June 26-28 at Fort Leonard Wood. Stop by the JPEO booth at the Nutter Field House to talk with a representative of .

On Thursday, June 28 from 0820 - 1030, LTC Gibson of JPMTMT’s EID-Flu Medical Countermeasure acquisition program will be part of the JPM Panel. He will present updates about . The panel session is in the Abrams Theater.

06/18/2012

More than 15,000 members of the biotechnology community from around the world are converging in Boston for the BIO International Convention. is there, too. Visit us at Booth 1020 and read about us in both of the convention daily newspapers.